Cargando…

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity

Intratumoral heterogeneity is frequently associated with tumor immune escape, with MHC-class I and antigen expression loss rendering tumor cells invisible to T cell killing, representing a major challenge for the design of successful adoptive transfer protocols for cancer immunotherapy. While CD8(+)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correia, Margareta P., Stojanovic, Ana, Wels, Winfried S., Cerwenka, Adelheid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758178/ https://www.ncbi.nlm.nih.gov/pubmed/35036073 http://dx.doi.org/10.1080/2162402X.2021.1973783

Ejemplares similares

Modulation of NKp30- and NKp46-Mediated Natural Killer Cell Responses by Poxviral Hemagglutinin
por: Jarahian, Mostafa, et al.
Publicado: (2011)

The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
por: Stojanovic, Ana, et al.
Publicado: (2018)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Expression Analysis of the Ligands for the Natural Killer Cell Receptors NKp30 and NKp44
por: Byrd, Andreina, et al.
Publicado: (2007)

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
por: Chretien, Anne-Sophie, et al.
Publicado: (2017)

Functional Differences between Human NKp44(−) and NKp44(+) RORC(+) Innate Lymphoid Cells
por: Hoorweg, Kerim, et al.
Publicado: (2012)

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
por: Chretien, Anne-Sophie, et al.
Publicado: (2019)

NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint
por: Shemesh, Avishai, et al.
Publicado: (2016)

Influenza A Virus Hemagglutinin and Other Pathogen Glycoprotein Interactions with NK Cell Natural Cytotoxicity Receptors NKp46, NKp44, and NKp30
por: Luczo, Jasmina M., et al.
Publicado: (2021)

Targeting Natural Killer Cell Reactivity by Employing Antibody to NKp46: Implications for Type 1 Diabetes
por: Yossef, Rami, et al.
Publicado: (2015)

NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death
por: Shemesh, Avishai, et al.
Publicado: (2018)

NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans
por: Parodi, Monica, et al.
Publicado: (2019)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

Dependence of innate lymphoid cell 1 development on NKp46
por: Wang, Yufeng, et al.
Publicado: (2018)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

NKp46(+) Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine
por: Luci, Carmelo, et al.
Publicado: (2015)

Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions
por: Garcia-Iglesias, Trinidad, et al.
Publicado: (2009)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

Human ILC3 Exert TRAIL-Mediated Cytotoxicity Towards Cancer Cells
por: Siegler, Jana-Julia, et al.
Publicado: (2022)

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
por: Han, Bin, et al.
Publicado: (2018)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Autoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage
por: Kasmani, Moujtaba Y, et al.
Publicado: (2022)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Migration Kinetics and Final Destination of Type 1 and Type 2 CD8 Effector Cells Predict Protection against Pulmonary Virus Infection
por: Cerwenka, Adelheid, et al.
Publicado: (1999)

Porcine CD8α(dim/-)NKp46(high) NK cells are in a highly activated state
por: Mair, Kerstin H, et al.
Publicado: (2013)

Hypercytotoxicity and Rapid Loss of NKp44(+) Innate Lymphoid Cells during Acute SIV Infection
por: Li, Haiying, et al.
Publicado: (2014)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
por: Peipp, Matthias, et al.
Publicado: (2015)

Differential Expression of LLT1, SLAM Receptors CS1 and 2B4 and NCR Receptors NKp46 and NKp30 in Pediatric Acute Lymphoblastic Leukemia (ALL)
por: Powers, Sheila B., et al.
Publicado: (2023)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

Contrasted TCRβ Diversity of CD8(+) and CD8(−) T Cells in Rainbow Trout
por: Castro, Rosario, et al.
Publicado: (2013)

Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N-Glycosylation
por: Skořepa, Ondřej, et al.
Publicado: (2020)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
por: Ni, Jing, et al.
Publicado: (2012)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Zbtb1 controls NKp46(+) ROR-gamma-T(+) innate lymphoid cell (ILC3) development
por: Lu, Ying, et al.
Publicado: (2017)

T-bet-dependent NKp46(+) innate lymphoid cells regulate the onset of T(H)17-induced neuroinflammation
por: Kwong, Brandon, et al.
Publicado: (2017)

The transcription factor HIF-1α mediates plasticity of NKp46(+) innate lymphoid cells in the gut
por: Krzywinska, Ewelina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3v9oqfui9i75bitnt9ns7aqpk6